<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742531</url>
  </required_header>
  <id_info>
    <org_study_id>50</org_study_id>
    <nct_id>NCT03742531</nct_id>
  </id_info>
  <brief_title>Does Induction Dosage in Latent Phase Affect Active Phase of Labor?</brief_title>
  <official_title>Does Induction Dosage in Latent Phase Affect Active Phase of Labor?A Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeynep Kamil Maternity and Pediatric Research and Training Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeynep Kamil Maternity and Pediatric Research and Training Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the need of oxytocin therapy in active phase of labor. there will be two
      groups treating with oxytocin in latent phase.One group will be treated with low dose
      oxytocin therapy and the other group will be treated with high dose oxytocin therapy.
      oxytocin treatment will be ceased at the beginning of the active phase of labor. the need of
      oxytocin treatment in active phase of labor will be compared between two groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxytocin treatment in active phase of labour is used with respect to clinicians preference
      and best approach has not been described. We want to investigate the effect of oxytocin
      treatment by using different regims in latent phase of labor when oxytocin treatment is
      ceased in active phase of labour. In our trial we discontinued oxytocin in active phase of
      labour and investigate which group needs oxytocin therapy due to inadequate uterine
      contractions and arrest of labor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>need for oxytocin retreatment</measure>
    <time_frame>an average of one year</time_frame>
    <description>need for oxytocin retreatment due to inadequate uterine contractions and labor arrest</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>length of active phase</measure>
    <time_frame>an average of one year</time_frame>
    <description>duration of acive phase of labor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ratio of caesarean section</measure>
    <time_frame>an average of one year</time_frame>
    <description>caesaraen section rate in total delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total oxytocin dose</measure>
    <time_frame>an average of one year</time_frame>
    <description>total amount of oxytocin treatment in latent and active phase of labor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APGAR scores</measure>
    <time_frame>an average of one year</time_frame>
    <description>neonatal 1 minute and 5-minute-APGAR scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Oxytocin</condition>
  <condition>Induction of Labor</condition>
  <arm_group>
    <arm_group_label>low dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oxytocin therapy starting with 2mU/min increased by 2 mU/min every 15 minutes. oxytocin will be stopped at the beginning of the active phase of labor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oxytocin therapy starting with 4mU/min increased by 4 mU/min every 15 minutes. oxytocin will be stopped at the beginning of the active phase of labor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin</intervention_name>
    <description>one group will be treated with low dose oxytocin and the other group will be treated with high dose oxytocin for augmentation of labor induction.</description>
    <arm_group_label>high dose group</arm_group_label>
    <arm_group_label>low dose group</arm_group_label>
    <other_name>synpitan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Live fetus in cephalic presentation, sonographically estimated fetal weight less than
             4200 g, undergoing induction of labor at 37-42 weeks of gestation, having indications
             of labor, no previous uterine surgery

        Exclusion Criteria:

          -  malpresentation, placenta previa, previous uterine surgery, multiple gestation, active
             genital herpes, non-reassuring fetal heart rate pattern
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>term pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ahmet eser</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zeynep Kamil Education and Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ahmet eser</last_name>
    <phone>00905067136880</phone>
    <email>hicoice@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ahmet eser</last_name>
    <phone>+902163910680</phone>
    <phone_ext>1316</phone_ext>
    <email>hicoice@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zeynep Kamil Education and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ahmet eser</last_name>
      <phone>905067136880</phone>
      <email>hicoice@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 25, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>November 14, 2018</last_update_submitted>
  <last_update_submitted_qc>November 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zeynep Kamil Maternity and Pediatric Research and Training Hospital</investigator_affiliation>
    <investigator_full_name>Ahmet Eser</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

